Liz Darlison
Overview
Explore the profile of Liz Darlison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang M, Bzura A, Baitei E, Zhou Z, Spicer J, Poile C, et al.
Nat Commun
. 2024 Aug;
15(1):7187.
PMID: 39168966
Malignant mesothelioma is a rare tumour caused by asbestos exposure that originates mainly from the pleural lining or the peritoneum. Treatment options are limited, and the prognosis is dismal. Although...
2.
Blyth K, Adusumilli P, Astoul P, Darlison L, Lee Y, Mansfield A, et al.
Lancet Respir Med
. 2024 May;
12(6):476-483.
PMID: 38740045
Most patients with pleural mesothelioma (PM) present with symptomatic pleural effusion. In some patients, PM is only detectable on the pleural surfaces, providing a strong rationale for intrapleural anticancer therapy....
3.
Gibson A, Ahmed W, Longworth L, Bennett B, Daumont M, Darlison L
Patient
. 2024 Apr;
17(5):551-563.
PMID: 38619810
Background: Malignant pleural mesothelioma (MPM) is a rare and usually fatal malignancy frequently linked to occupational asbestos exposures and associated with poor prognosis and considerable humanistic burden. The study aimed...
4.
Lond B, Dodd C, Davey Z, Darlison L, McPhelim J, Rawlinson J, et al.
Eur J Oncol Nurs
. 2024 Mar;
70:102564.
PMID: 38554615
Purpose: Clinical research trials are needed to enhance the medical care and treatment for lung cancer, which remains the leading cause of cancer-related deaths worldwide. While clinical trials allow for...
5.
Fennell D, Griffiths D, Eminton Z, Morgan-Fox A, Hill K, Ewings S, et al.
BMJ Open
. 2023 Nov;
13(11):e073120.
PMID: 37993149
Background: Malignant mesothelioma is a rapidly lethal cancer that has been increasing at an epidemic rate over the last three decades. Targeted therapies for mesothelioma have been lacking. A previous...
6.
Hargreaves S, Gardiner C, Tod A, Darlison L
Br J Community Nurs
. 2023 May;
28(5):248-252.
PMID: 37130714
Background: Mesothelioma is a rare cancer without cure. Clinical guidelines recommend the timely provision of palliative/supportive care; however, a new study identified barriers to achieving this ambition. Objective: The study...
7.
Hargreaves S, Clayton K, Creech L, Darlison L, Ejegi-Memeh S, Fenemore J, et al.
Eur J Oncol Nurs
. 2022 Oct;
61:102207.
PMID: 36240682
Purpose: The covid-19 global pandemic has impacted on nurses who have rapidly adapted to new ways of working, and experienced negative impacts due to over-stretched services. Two surveys captured the...
8.
Fennell D, Porter C, Lester J, Danson S, Taylor P, Sheaff M, et al.
EClinicalMedicine
. 2022 Jun;
48:101432.
PMID: 35706488
Background: Currently, there is no US Food and Drug Administration approved therapy for patients with pleural mesothelioma who have relapsed following platinum-doublet based chemotherapy. Vinorelbine has demonstrated useful clinical activity...
9.
Lond B, Quincey K, Apps L, Darlison L, Williamson I
Health Psychol
. 2022 Feb;
41(5):343-355.
PMID: 35201802
Objective: Mesothelioma is a life limiting cancer caused by previous exposure to asbestos. Due to the continued use of asbestos products internationally, the condition presents an increasing risk to global...
10.
Harrison M, Darlison L, Gardiner C
J Palliat Care
. 2022 Feb;
37(2):197-203.
PMID: 35171747
Mesothelioma is a rare, progressive cancer with a short trajectory from diagnosis to the end of life. This study explores the experiences of palliative and end of life care for...